Levetiracetam as adjunctive therapy for refractory anxiety disorders

Journal of Clinical Psychiatry

Volumn 68, Issue 7, 2007, Pages 1010-1013

  Kinrys, Gustavo ^a,c   Worthington, John J ^b,c   Wygant, Lisa ^a   Nery, Fernanda ^a,c   Reese, Hannah ^b   Pollack, Mark H ^b,c  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CITALOPRAM; CLONAZEPAM; CLONIDINE; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; LORAZEPAM; PAROXETINE; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADJUVANT THERAPY; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 34548315740     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0705     Document Type: Article

References (22)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
2. Ballenger JC. Current treatment of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579-1594
3. Clark RD, Canive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999;12:395-401
4. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348
5. Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18:169-172
6. Stahl SM. Symptoms and circuits, pt 2: anxiety disorders. J Clin Psychiatry 2003;64:1408-1409
7. Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry 2004;65:149-150
8. Noyer M, Gillard M, Montagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;286:137-146
9. Niespodziany I, Klitgaard H, Margineanu DG, et al. Levetiracetam: modulation of high-voltage-activated Ca2+ current in CA1 pyramidal neurons of rat hippocampal slices [abstract]. Epilepsia 2000;41(suppl 7):37
10. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866
11. Lamberty Y, Gower AJ, Klitgaard H. The new antiepileptic drug levetiracetam normalizes chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002;439:101-106
12. Lamberty Y, Falter U, Gower AJ, et al. The novel drug levetiracetam (Keppra) reveals an anxiolytic profile in the punished drinking test which differs from chlordiazepoxide [poster]. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 2002; San Juan, Puerto Rico
13. Jain KK. An assessment of levetiracetam as an anti-epileptic drug. Expert Opin Investig Drugs 2000;9:1611-1624
14. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA 2004;291:615-620
15. Leppik IE. Three new drugs for epilepsy: levetiracetam, oxcarbezapine, and zonisamide. J Child Neurol 2002;17(suppl 1):S53-S57
16. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004;65:1219-1222
17. Kinrys G, Wygant LE, Pardo TB, et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67:211-214
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-1779
20. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related posttraumatic stress disorder. Psychopharmacology (Berl) 2004;175:451-456
21. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11
22. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006;59:211-215